DR-70 is off patent. Anyone can make it and sell it without any royalties paid. Uni Pharma is doing it. GCDX is doing it.
CIT is too old to develop before going off patent. It is worthless just as Radient stated in their last 10K.
So, what would be left is the shell.
Read these two articles from the SEC and you then decide if the shell has any value.
About reverse mergers.
"Why Pursue a Reverse Merger? A private operating company may pursue a reverse merger in order to facilitate its access to the capital markets, including the liquidity that comes with having its stock quoted on a market or listed on an exchange. Private operating companies generally have access only to private forms of equity, while public companies potentially have access to funding from a broader pool of public investors. A reverse merger often is perceived to be a quicker and cheaper method of “going public” than an initial public offering (IPO). The legal and accounting fees associated with a reverse merger tend to be lower than for an IPO. And while the public shell company is required to report the reverse merger in a Form 8-K filing with the SEC, there are no registration requirements under the Securities Act of 1933 as there would be for an IPO. In addition, being public may give a company increased value in the eyes of potential acquirers."
Radient is no longer a public company. Any acquiring company would have to go through the lengthy and expensive process to regain the ticker symbol.
FINRA controls the ticker symbols and making Radient public again would not be a cost effective method of going public for any acquiring company.
I have never shorted nor intend to have any financial interest in this stock. I am not connected with anyone who trades, shorts or has financial interests in this stock. I only post facts and my opinions. I do not post on IHUB with different aliases.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.